FCN-647 is a proprietary, selective and potent inhibitor of BTK (Bruton’s tyrosine kinase) developedby Fochon for the treatment of lymphoma. BTK is a key regulator of the B-cell receptor (BCR) signaling pathway and dysregulated BCR signaling has been implicated in the survival of malignant B-cells, resulting in cancers that form in B cells, called B-cell malignancies (eg.  chronic lymphocytic leukemia, mantle cell lymphoma and Waldenström’s macroglobulinemia).

FCN-647 demonstrated enhanced in vitro and in vivo anti-cancer potency compared to approved BTK inhibitor Ibrutinib (PCI-32765), with excellent pharmakinetic and drug safety properties.

Mechanism of Action